ARTICLE | Clinical News
LB-100: Ph I data
January 13, 2017 8:28 PM UTC
An open-label, dose-escalation, U.S. Phase I trial in 20 evaluable patients with solid tumors showed that once-daily IV LB-100 on days 1-3 of each 21-day cycle led to 1 partial response in a patient w...
BCIQ Company Profiles
BCIQ Target Profiles